Organisation paid for research Program year 2025 Source: CMS Open Payments

Palm Research Center Inc

Neither a doctor nor a teaching hospital

Research payments

$17,924,748

768 payments

Through program year 2025, Palm Research Center Inc is reported as receiving $17,924,748 in research payments, across 768 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,002,541 72
2024 Research $3,200,693 70
2023 Research $3,490,544 63
2022 Research $1,441,548 79
2021 Research $1,965,837 149
2020 Research $1,341,937 172
2019 Research $2,481,649 163

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $14,613,773 251 payments
  2. Amgen Inc. $1,515,963 59 payments
  3. AbbVie, Inc. $588,801 56 payments
  4. Sanofi US Services Inc. $548,931 189 payments
  5. Novo Nordisk AS $304,302 64 payments
  6. Ascendis Pharma, Inc. $66,963 15 payments
  7. Pfizer Inc. $48,061 6 payments
  8. Ionis Pharmaceuticals, Inc. $40,549 11 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $37,160 30 payments
  10. F. Hoffmann-La Roche AG $36,100 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $1,387,725 4 payments
  2. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $1,238,394 5 payments
  3. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $943,028 9 payments
  4. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities (Attain-Maintain) $930,556 6 payments
  5. A Study of Ly3209590 in Participants With Type 2 Diabetes Mellitus $890,385 9 payments
  6. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $854,179 4 payments
  7. A Phase 2, Randomized, Parallel, Open-Label Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy $851,047 12 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity Or Overweight (Surpass-T1d-1) $851,011 2 payments
  9. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $827,931 24 payments
  10. A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $669,967 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record